Pharmaceuticals China

China Diabetes Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

China Diabetes Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $5.90 Bn Placeholder estimate
Estimate 2025 $6.39 Bn 8.2% of the global market
Projected 2034 $13.10 Bn 105% Adds $6.71 Bn over 9 forecast years
CAGR 2025–2034 8.3% Faster than 32% of 183 Pharmaceuticals markets here
Key players 6 +1
  • China is 8.21% of the global market.
  • In APAC, the largest is China (this report) at $6.39 Bn.
  • Fastest growing: India at 10% a year.
  • China ranks 1st of 14 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$6.71 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Diabetes Drugs Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $5.90 Bn — —
2025 (base) $6.39 Bn +$489.8 Mn —
2026 (forecast) $6.92 Bn +$530.5 Mn +8.3%
2027 (forecast) $7.50 Bn +$574.5 Mn +17.3%
2028 (forecast) $8.12 Bn +$622.2 Mn +27%
2029 (forecast) $8.79 Bn +$673.8 Mn +37.6%
2030 (forecast) $9.52 Bn +$729.7 Mn +49%
2031 (forecast) $10.31 Bn +$790.3 Mn +61.4%
2032 (forecast) $11.17 Bn +$855.9 Mn +74.7%
2033 (forecast) $12.10 Bn +$927.0 Mn +89.2%
2034 (forecast) $13.10 Bn +$1.00 Bn +105%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Diabetes Drugs Market Analysis at a glance
Market size, 2025$6.39 Bn placeholder estimate
Forecast, 2034$13.10 Bn placeholder estimate
Growth (CAGR), 2025–20348.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and 1 more (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Diabetes Drugs Market Analysis Executive Summary

Diabetes drugs lower blood sugar in people with type 1 or type 2 diabetes, including insulin, pills and injectable GLP-1 medicines.

Key segments of the diabetes drugs market include drug class (Insulin, GLP-1 Agonists and SGLT2 Inhibitors) and route (Oral and Injectable).

Bar chart: China Diabetes Drugs market size, 2024–2034, placeholder estimates. $5.90 Bn in 2024, $6.39 Bn in 2025 and $13.10 Bn in 2034, 8.3% CAGR.
China Diabetes Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Diabetes Drugs Market Dynamics

Market Growth Drivers

Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.

Opportunity

Connected devices, lower-priced sensors and new insulins and pills give the diabetes drugs market room to grow.

Market Restraints

High costs for people without cover, price competition and uneven access to care in low-income countries hold back the diabetes drugs market.

Competitive Landscape for Diabetes Drugs Market in China

The diabetes drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Diabetes Drugs Market in China

Diabetes Drugs in China: rules, payment and health figures

Drugs need approval from the National Medical Products Administration (NMPA) before sale.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] Diabetes (ages 20–79): 11.9% of people 20–79 in 2024, the latest World Bank figure for China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 20 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for diabetes drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Diabetes Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Diabetes Drugs in context

China compared

  • Diabetes (ages 20–79): 11.9% of people 20–79 (2024). World: 10.8% of people 20–79 (2024). 4th highest of the 18 countries we cover in APAC.[1]
  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 17 countries we cover in APAC.[2]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 17 countries we cover in APAC.[3]

[1] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 20 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Diabetes Drugs market in China?
Placeholder estimate: about $6.39 Bn in 2025, rising to about $13.10 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Diabetes Drugs market in China growing?
Placeholder estimate: about 8.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Diabetes Drugs market report cover?
The report splits the market by drug class (Insulin, GLP-1 Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors and more), route (Oral, Injectable) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Diabetes Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and Boehringer Ingelheim GmbH.
What is driving the Diabetes Drugs market?
Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.
Who regulates Diabetes Drugs in China?
Drugs need approval from the National Medical Products Administration (NMPA) before sale. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
What does World Bank report for China?
Diabetes (ages 20–79): 11.9% of people 20–79 in 2024, the latest World Bank figure. Source: World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 20 Nov 2026.
How many people in China are 65 or older?
14.9% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 21 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in China

See all

Related on diabetes

See the topic